Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SL Science HoldingSLBT +24.39%12 PB Ratio is 822.50 as of Aug. 03, 2026, which is 23% below its 10-year median of 1,075.00. GuruFocus rates SLBT with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 1,230 Biotechnology companies, SL Science Holding ranks worse than 99.92% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
SL Science Holding PB Ratio Related Terms
SL Science Holding PB Ratio Historical Data
* Premium members only.
The historical data trend for SL Science Holding's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SL Science Holding PB Ratio Chart
SL Science Holding Annual Data
Trend
Dec23
Dec24
Dec25
PB Ratio
0.00
0.00
0.00
SL Science Holding Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
PB Ratio
0.00
0.00
0.00
0.00
0.00
SLBT vs DMRA, BCAX, TYRA: PB Ratio Comparison
For the Biotechnology subindustry, SL Science Holding's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SL Science Holding PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SL Science Holding's PB Ratio distribution charts can be found below:
* The bar in red indicates where SL Science Holding's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
SL Science Holding (SLBT) has a PB Ratio of 822.50 as of Aug. 03, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on SL Science Holding and its competitors. This is 23% below median its historical median of 1,075.00. Over the past decade, SL Science Holding's PB Ratio has ranged from 661.25 to 1,497.50. According to the industry distribution chart, SL Science Holding ranks #1229 out of 1230 companies in the Biotechnology industry, placing it in the top 99.9%.
Is SL Science Holding's PB Ratio too high?
SL Science Holding's current PB Ratio of 822.50 is 23% below median its 10-year median of 1,075.00. Over the past 10 years, this metric has ranged from a low of 661.25 to a high of 1,497.50. The Biotechnology industry median PB Ratio is 2.75. SL Science Holding's value of 822.50 is 29863.6% above this industry median. Based on the distribution chart, SL Science Holding ranks #1229 out of 1230 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SL Science Holding has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SL Science Holding's PB Ratio compare to DMRA and BCAX?
According to the Biotechnology industry distribution chart, SL Science Holding ranks #1229 out of 1230 companies for PB Ratio. This places SL Science Holding in the lower half of its industry. The industry median PB Ratio is 2.75. SL Science Holding's value of 822.50 is 29863.6% above this benchmark. Historically, SL Science Holding's own PB Ratio has ranged from 661.25 to 1,497.50 over the past decade. While the company's 10-year median is 1,075.00 vs. the industry median of 2.75, SL Science Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.75, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SL Science Holding's current PB Ratio of 822.50 is 29863.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on SL Science Holding and its competitors. For the Biotechnology industry, the median PB Ratio is 2.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SL Science Holding's current PB Ratio is 822.50, which is 23% below median its own 10-year median of 1,075.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SL Science Holding stock overvalued right now?
SL Science Holding (SLBT) has a current PB Ratio of 822.50. The current PB Ratio is 822.50, which is 23% below median its 10-year median of 1,075.00 and 29863.6% above the Biotechnology industry median of 2.75. SL Science Holding's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For SL Science Holding (SLBT), the current PB Ratio is 822.50 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
12GF Score
Get the complete analysis for SLBT
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLBT has been successfully added to your 
